enCore Energy Corp. has completed the distribution of 35 million Verdera Energy Corp. shares as a special dividend to its shareholders, giving them direct ownership in Verdera's uranium assets in New Mexico. The distribution included both unrestricted and restricted shares, with enCore retaining a significant stake in Verdera. This move separates Verdera with its own shareholder base and management team, allowing enCore to focus on its other uranium projects while maintaining exposure to Verdera's progress. The companies aim to strengthen domestic uranium supply in the U.S.
The distribution of Verdera common shares by enCore Energy provides context for readers. For those following the Basic Materials sector, 9 out of 38 US stocks traded on Pluang rose while 28 fell as of Oct 02, 2026 02:41 WIB. Notable prices include APD at USD 272.65 with a 1-day change of -1.36%, ECL at USD 271.46 down 1.21%, and FCX at USD 69.15 down 1.20%.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
